Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis
- First Online:
A number of reviews have claimed that the selective serotonin and noradrenalin re-uptake inhibitor venlafaxine is more effective than selective serotonin re-uptake inhibitors (SSRIs) in achieving remission and symptom reduction in major depression.
The aim of this study was to systematically review studies on the efficacy of venlafaxine vs SSRI and to evaluate the influence of methodological issues on the effect sizes.
Materials and methods
Following a systematic literature search, we pooled data on depression scores, response, remission and dropout rates. We also performed sub-group analyses.
Seventeen studies were included. We found no significant superiority in remission rates (risk ratio [RR] = 1.07, 95% confidence intervals [95%CI] = 0.99 to 1.15, numbers needed to treat [NNT] = 34) and a small superiority in response rates (RR = 1.06, 95%CI = 1.01 to 1.12, NNT = 27) over SSRIs. There was a small advantage to venlafaxine in change scores (effect size = −0.09, 95%CI = −0.16 to −0.02, p = 0.013), which did not reach significance when post-treatment scores were used (effect size = −0.06, 95%CI = −0.13 to 0.00). Discontinuation rates due to adverse events were 45% higher in the venlafaxine group. The main reasons for the differences between this analysis and previous reviews were the exclusion of studies with methodological limitations, avoiding to pool selectively reported study results and exclusion of studies available as abstracts only.
Our analysis does not support a clinically significant superiority of venlafaxine over SSRIs. Differences between our study and previous reviews were not accounted for by technical aspects of data synthesis, but rather by study selection and choice of outcome parameters.
KeywordsVenlafaxine Anti-depressant Meta-analysis Systematic review
- Alves C, Cachola I, Brandao J (1999) Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Companion J Clin Psychiatry 5:57–63Google Scholar
- American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157:1–45Google Scholar
- Borenstein M, Hedges L, Higgins J, Rothstein H (2005) Comprehensive meta-analysis, version 2. Biostat, Englewood, NJGoogle Scholar
- Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ Books, LondonGoogle Scholar
- Fochtman LJ, Gelenberg A, Fochtman LJ (2006) Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition. Available at: http://www.psych.org/psych_pract/treatg/pg/MDD.watch.pdf. Accessed October 6, 2006
- Geddes JR, Freemantle N, Mason J (2006) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (Cochrane Review). In: The Cochrane Library, Issue 3, 2006. Update Software, OxfordGoogle Scholar
- MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326:1014PubMedCrossRefGoogle Scholar
- McPartlin GM, Reynolds A, Anderson C, Casoy J (1998) A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Companion J Clin Psychiatry 4:127–132Google Scholar
- National Institute for Health and Clinical Excellence (2004) Management of depression in primary and secondary care. National Clinical Practice Guideline Number 23. Available at: http://www.nice.org.uk/CG023NICEguideline. Accessed October 13, 2006
- Salinas E, Venlafaxine-XR-Study-Group (1997) Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 42(Suppl I):297SGoogle Scholar
- Tylee A, Beaumont G, Bowden MW, Reynolds A (1997) A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Companion J Clin Psychiatry 3:51–58Google Scholar